



# UK Interdisciplinary Breast Cancer Symposium 2022

On-Line Meeting

Monday 24<sup>th</sup> & Tuesday 25<sup>th</sup> January 2022



# UKIBCS 2022

**Monday 24th January 2022**

<b>09:00–09:05</b>	<b>WELCOME from Andreas Makris, Chair UKIBCS Organising Committee</b>
<b>09:05-10:45</b>	<b>SESSION 1: Early Breast Cancer – Local Treatment</b>
	<b>Chairs:</b> <i>Chris Holcombe</i> , Consultant Oncoplastic Breast Surgeon, Royal Liverpool University Hospital & <i>Sarah Vinnicombe</i> , Consultant Radiologist, Thirlestaine Breast Centre, Cheltenham
	<b>09:05</b> <b>Minimally invasive techniques for therapeutic treatment of cancers</b> <i>Nisha Sharma</i> , Director of Breast Screening and Clinical Lead for Breast Imaging, Leeds Teaching Hospital NHS Trust
	<b>09:25</b> <b>Risk-adapted tailored breast radiotherapy: one size no longer fits all</b> <i>Charlotte Coles</i> , Reader in Breast Radiation Research, Cancer Research UK Cambridge Centre
	<b>09:45</b> <b>Risk-adapted axillary surgery including TAD and its practical aspects</b> <i>Amit Goyal</i> , Consultant Oncoplastic Breast Surgeon, Royal Derby Hospital
	<b>10:05</b> <b>What's new in DCIS: A grand challenge</b> <i>Alastair Thompson</i> , Olga Keith Wiess Chair of Surgery, Baylor College of Medicine, Houston, Texas
	<b>10:25</b> Panel discussion
<b>10:45</b>	<b>BREAK</b>
<b>11:15 – 12:55</b>	<b>SESSION 2: Early Breast Cancer – Systemic Treatment</b>
	<b>Chairs:</b> <i>Judith Bliss</i> , Professor of Clinical Trials, The Institute of Cancer Research, London & <i>Mairead Mackenzie</i> , Patient Advocate
	<b>11:15</b> <b>Pre-surgical provocation tests for clinical trials and management</b> <i>Mitch Dowsett</i> , Head of the Academic Department of Biochemistry, Royal Marsden Hospital
	<b>11:35</b> <b>Are CDK 4/6 inhibitors ready for clinical use?</b> <i>Nadia Harbeck</i> , Director, Breast Centre, LMU University Hospital, Munich, Germany
	<b>11:55</b> <b>Optimising systemic therapy for women with BRCA mutations: current knowledge and future directions</b> <i>Andrew Tutt</i> , Head of Division of Breast Cancer Research & Director, Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research
	<b>12:15</b> <b>Neoadjuvant antiHer2 therapy enabled risk adaptation: an era to optimise practice</b> <i>Iain MacPherson</i> , Clinical Senior Lecturer in Medical Oncology, University of Glasgow
	<b>12:35</b> Panel discussion
<b>12.55</b>	<b>LUNCH</b>

# Monday 24th January 2022

<b>13:40 – 15:20</b>	<b>SESSION 3: Prevention and Early Diagnosis</b>
	<b>Chairs:</b> <i>Sarah Pinder</i> , Chair of Breast Pathology, King's College London & <i>Gareth Evans</i> , Professor of Medical Genetics and Cancer Epidemiology, University of Manchester
	<b>13:40</b> <b>Molecular evolution of breast cancer</b> <i>Lucy Yates</i> , Clinical Career Development Fellow, Wellcome Sanger Institute
	<b>14:00</b> <b>Personalised breast cancer screening</b> <i>Fiona Gilbert</i> , Professor of Radiology, University of Cambridge School of Clinical Medicine
	<b>14:20</b> <b>Past, present and future directions in breast cancer genetics</b> <i>Douglas Easton</i> , Professor of Genetic Epidemiology, University of Cambridge
	<b>14:40</b> <b>Strategies to prevent breast cancer</b> <i>Kelly-Anne Phillips</i> , Medical Oncologist and Senior Strategic Research Leader, Peter MacCallum Cancer Centre, Melbourne, Australia
	<b>15:00</b> <b>Panel discussion</b>

<b>15:20</b>	<b>BREAK</b>
--------------	--------------

<b>15:45 – 17:25</b>	<b>SESSION 4: Metastatic Breast Cancer</b>
	<b>Chairs:</b> <i>Caroline Wilson</i> , Consultant Medical Oncologist, Sheffield Teaching Hospital NHS Foundation Trust & <i>Leena Chagla</i> , Vice President ABS, Head of Breast Unit, St Helens and Knowsley Teaching Hospitals NHS Trust
	<b>15:45</b> <b>Should we be offering next generation sequencing for routine clinical use?</b> <i>Fabrice André</i> , Head of Research and Professor Department of Medical Oncology, Institut Gustave Roussy Villejuif, France
	<b>16:05</b> <b>Immunotherapy for metastatic breast cancer</b> <i>Peter Schmid</i> , Professor of Cancer Medicine, Cancer Research UK
	<b>16:25</b> <b>Optimal management and treatment sequencing of ER+ HER2- metastatic breast cancer</b> <i>Stephen Johnston</i> , Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust
	<b>16:45</b> <b>Role of surgery in metastatic breast cancer</b> <i>Nita Nair</i> , Professor and Consultant Surgeon, Tata Memorial Centre, Mumbai, India
	<b>17:05</b> <b>Panel discussion</b>

<b>17:25</b>	<b>BREAK</b>
--------------	--------------

<b>18:00 – 19:00</b>	<b>PROMOTIONAL INDUSTRY-LED SYMPOSIUM ORGANISED AND FUNDED BY GILEAD SCIENCES LTD.</b>
----------------------	--

## Tuesday 25th January 2022

<b>07:45 - 08:45</b>	<b>INDUSTRY SYMPOSIUM: SANOFI</b>
	<b>Putting the patient at the centre of Er+ Her2- Mbc decision making</b>
	<b>07:45</b> <b>Welcome &amp; presentation: Milestones and developments in the ER+ HER2- mBC treatment landscape</b> <b>Chair:</b> Stephen Johnston, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust
	<b>07:50</b> <b>The evolving ER+ HER2- mBC treatment landscape</b> <i>Simon Lord</i> , Consultant Medical Oncologist, Oxford University Hospitals NHS Foundation Trust
	<b>08:03</b> <b>Addressing treatment challenges for ER+ HER2- mBC specific patient populations</b> <i>Nicolò Matteo Luca Battisti</i> , Senior Clinical Research Fellow in medical Oncology, Royal Marsden NHS Foundation Trust
	<b>08:16</b> <b>Enhancing treatment adherence and QoL in ER+ HER2- mBC</b> <i>Dame Lesley Fallowfield</i> , Professor of Psycho-oncology, Brighton & Sussex Medical School, University of Sussex.
	<b>08:29 - 08:45</b> <b>Live Q&amp;A with the Panel</b> Moderated by <i>Stephen Johnston</i>
<b>09:10 – 10.55</b>	<b>SESSION 5: Translational/Basic Science</b>
	<b>09:10</b> <b>Welcome and Introduction</b> <b>Chairs:</b> <i>Ingunn Holen</i> , Professor of Bone Oncology, The University of Sheffield & <i>Thomas Hughes</i> , Associate Professor of Cancer Biology at the University of Leeds
	<b>09:15</b> <b>Co-targeting CDK4/6 and AKT with endocrine therapy overcomes CDK4/6 inhibitor and endocrine therapy resistance in preclinical breast cancer models</b> <i>Henrik J. Ditzel</i> , Head of Research, Department of Oncology, Institute of Clinical Research, Odense University Hospital, Denmark
	<b>09:40</b> <b>The challenge of modelling of brain metastases - combining in vivo, cell culture and organotypic approaches to investigate brain extravasation</b> <i>Georgia Mavria</i> , University of Leeds
	<b>10:05</b> <b>The role of gamma delta T cells in breast cancer development/metastasis</b> <i>Seth Coffelt</i> , Senior Research Fellow, Beatson Institute for Cancer Research, University of Glasgow
	<b>10:30</b> <b>Understanding breast cancer through use of single-cell systems biology</b> <i>Bernd Bodenmiller</i> , Professor for Quantitative Biomedicine, ETH Zurich, University of Zurich
	<b>10:55</b>
<b>BREAK</b>	
<b>11:20-13:05</b>	<b>SESSION 6: Living with and beyond breast cancer</b>
	<b>Chairs:</b> <i>Anne Armstrong</i> , Consultant Medical Oncologist, The Christie, Manchester, Independent Cancer Patients' Voice (ICPV) and <i>Lesley Turner</i> , Patient Advocate, Independent Cancer Patients' Voice (ICPV)
	<b>11:25</b> <b>Unmet need and follow-up</b> <i>Janet Dunn</i> , Professor of Clinical Trials, University of Warwick
	<b>11:50</b> <b>Breast Cancer Now's Helpline and patient focused resources</b> <i>Jane Murphy</i> , Senior Nurse Helpline and Ask Our Nurse Service
	<b>12:15</b> <b>Identifying theory and evidence-based psychosocial factors associated with adherence to adjuvant hormonal therapy: understanding individual differences to tailor interventions</b> <i>Lyndsay Hughes</i> , Programme Director of MSc Health Psychology, King's College London
	<b>12:40</b> <b>Supporting women with adherence to endocrine therapy following breast cancer: the SWEET programme</b> <i>Linda Sharp</i> , Professor of Cancer Epidemiology, Newcastle University
<b>13:05 – 13:45</b>	
<b>LUNCH</b>	

## Tuesday 25th January 2022

<b>13:45-15:30</b>	<b>SESSION 7: Breast cancer management and research: Our vision for the future</b>
	<p><b>13:45</b> Introduction Chairs: <i>Baroness Delyth Morgan</i>, Chief Executive, Breast Cancer Now &amp; <i>Catherine Harper-Wynne</i>, Consultant Medical Oncologist and Honorary Senior Lecturer University of Kent, Kent Oncology Centre</p>
	<p><b>13:50</b> Future of cancer services in the UK <i>Dame Cally Palmer</i>, National Cancer Director, NHS England &amp; Improvement</p>
	<p><b>14:00</b> Future vision for breast surgery <i>Raghavan Vidya</i>, Consultant Oncoplastic Breast &amp; General Surgeon, Royal Wolverhampton Hospital</p>
	<p><b>14:10</b> Future vision for radiotherapy <i>Imogen Locke</i>, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust</p>
	<p><b>14:20</b> Future vision for pathology <i>Sarah Pinder</i>, Chair of Breast Pathology, King's College London</p>
	<p><b>14:30</b> Future vision for radiology <i>Sarah Vinnicombe</i>, Consultant Radiologist, Thirlestaine Breast Centre, Cheltenham</p>
	<p><b>14:40</b> Future vision for clinical trials <i>Judith Bliss</i>, Professor of Clinical Trials, Institute of Cancer Research, London</p>
	<p><b>14:50</b> Future vision for systemic therapies <i>Mark Verrill</i>, Consultant Medical Oncologist, Freeman Hospital, Newcastle</p>
	<p><b>15:00</b> Panel discussion</p>
<b>15:30</b>	<b>BREAK</b>
<b>16:00 – 17:00</b>	<b>INDUSTRY SYMPOSIUM: LILLY</b>
	<p>Evolution in MBC patient care; a scientific, clinical and patient management update (contains Lilly promotional content)</p>
	<p><b>16:00</b> Welcome and introduction Chair: <i>Dr Mark Verrill</i>, Consultant Medical Oncologist, Northern Centre for Cancer Care, Newcastle-upon-Tyne</p>
	<p><b>16:05</b> Molecular mechanisms of primary &amp; acquired resistance to endocrine therapy: the way forward <i>Dr Mark Verrill</i>, Consultant Medical Oncologist, Northern Centre for Cancer Care, Newcastle-upon-Tyne</p>
	<p><b>16:25</b> Clinical characteristics of patients with complete response to abemaciclib▼-based endocrine therapy in Monarch 2 and Monarch 3 <i>Dr Fharat Raja</i>, Consultant Medical Oncologist, UCLH and North Middlesex University Hospital, London</p>
	<p><b>16:40</b> Patient consultation and management of adverse effects <i>Maria Noblet R.N.</i>, Consultant Nurse, Portsmouth Hospitals NHS Trust, Portsmouth</p>
	<p><b>16:50</b> Panel discussion and Q&amp;A, All panel</p>
<b>17:00</b>	<b>BREAK</b>

**17:30 – 18.00**

**INDUSTRY SYMPOSIUM: EXACT SCIENCES**

**Follow the evidence to help guide chemotherapy decisions for early breast cancer patients**

**Welcome & Introduction:** *Dr Mark Verrill*, Consultant Medical Oncologist, Northern Centre for Cancer Care, Newcastle-upon-Tyne

**Summary of the RxPONDER publication**

*Dr Mark Verrill*, Consultant Medical Oncologist, Northern Centre for Cancer Care, Newcastle-upon-Tyne

**Case Study Discussion – What does this mean for patients?**

*Mark Verrill*, Northern Centre for Cancer Care, Newcastle-upon-Tyne & *Marianne Dillon*, Swansea bay University Health ~Board

**Q&A Session**

**Hosted by:**

# BREAST CANCER NOW

The research  
& care charity

**In partnership with:**



**British Breast Group**



## GOLD SPONSORS

**EXACT  
SCIENCES**

 **GILEAD**  
Creating Possible

*Lilly* | ONCOLOGY

 **Roche**

**SANOFI GENZYME** 

Exact Sciences has had no input or influence on the agenda

The UKIBCS is supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at the UKIBCS.

Lilly are supporting this meeting through sponsorship and have no control over the overall agenda or logistics of this event.

Roche has provided sponsorship for the educational/scientific content of this meeting only. Roche has not been involved with or influenced the content, agenda or speaker selection.

Sanofi Genzyme are supporting this meeting through sponsorship and have had no control over the agenda, educational content or logistics of this event.

## SILVER SPONSORS

 **Eisai**

  
**Pierre Fabre**

 **veracyte.**

Pierre Fabre has funded the educational/scientific content of this meeting only. It has not been involved with or influenced the content, agenda or speaker selection.